Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zenas BioPharma (ZBIO) EBITDA Margin (2023 - 2025)

Zenas BioPharma has reported EBITDA Margin over the past 3 years, most recently at 336.26% for Q1 2025.

  • Quarterly results put EBITDA Margin at 336.26% for Q1 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was 3779.95% (down 64337.0% YoY), and the annual figure for FY2025 was 3779.95%, down 64333.0%.
  • EBITDA Margin for Q1 2025 was 336.26% at Zenas BioPharma, up from 1049.26% in the prior quarter.
  • Over the last five years, EBITDA Margin for ZBIO hit a ceiling of 71.23% in Q3 2023 and a floor of 1049.26% in Q4 2024.
  • Median EBITDA Margin over the past 3 years was 336.26% (2025), compared with a mean of 438.1%.